SynthesisCanadian journal of gastroenterology & hepatology2018
A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for
Synthesis in Canadian journal of gastroenterology & hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of Intestinal Microbiota Transplantation In Patients With Chronic Heart Failure
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Safety and efficacy of fecal microbiota transplantation versus antibiotics for treating clostridioides difficile infection: systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Efficacy of probiotic adjuvant therapy for irritable bowel syndrome in children: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020Guideline
- Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyondAnnals of medicinePooled it
- Dynamics in Circulating Immune Cell Subsets After Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.Clinical and translational gastroenterology · 2026Trial
- Fecal Microbiota Transplantation and Microbiota-Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions.Clinical pharmacology and therapeutics · 2026Review
- Gut Microbiota Alterations in People Living With HIV: Dysbiosis, Immune Dysfunction and Therapeutic Perspectives.Reviews in medical virology · 2026Review
- Article
- Fecal Microbiota Transplantation Is Associated with Better Survival Compared to Standard of Care in Severe Alcoholic Hepatitis Not Responding to Corticosteroids: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- The gastrointestinal microbiome and constituent short-chain fatty acids: a narrative review of an underexplored axis in acute lymphoblastic leukemia.Gut pathogens · 2026Review
- Biovigilance in Faecal Microbiota Transplantation: 7-Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events.United European gastroenterology journal · 2026Observational
- The gut microbiome in solid-organ and haematopoietic-stem-cell transplantation.Nature reviews. Microbiology · 2026Review
- The gut-lung axis in ARDS: beyond microbial translocation.Respiratory research · 2026Review
- Environmentally mediated interactions predict community assembly and invasion success in a gut microbiota synthetic community.mSystems · 2026Article
- Translational approaches in microbiome research: from functional mechanisms to next-generation therapeutics.Frontiers in microbiology · 2026Review
- Fecal microbiota transplantation promotes gut microbiome recovery in pediatric hematopoietic stem cell transplant recipients.Frontiers in microbiomes · 2026Article
- Intestinal microecology: a crucial factor influencing incomplete immune reconstitution after antiretroviral therapy in people living with HIV-1.Frontiers in public health · 2026Review
- Microbiome dysbiosis and chemotherapy resistance in acute myeloid leukemia (AML).NPJ biofilms and microbiomes · 2025Review
- From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy.Gut microbes · 2025Review
- Targeting Gut-Lung Crosstalk in Acute Respiratory Distress Syndrome: Exploring the Therapeutic Potential of Fecal Microbiota Transplantation.Pathogens (Basel, Switzerland) · 2025Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fecal microbiota transplantation (FMT) has been shown to be effective in recurrent Methods: We searched MEDLINE and EMBASE for English language articles published on FMT for treatment of CD infection in immunocompromised patients (including patients on immunosuppressant medications, patients with human immunodeficiency virus (HIV), inherited or primary immunodeficiency syndromes, cancer undergoing chemotherapy, or organ transplant, including-bone marrow transplant) of all ages. We excluded inflammatory bowel disease patients that were not on immunosuppressant medications. Resolution and adverse event rates (including secondary infection, rehospitalization, and death) were calculated. Results: Forty-four studies were included, none of which were randomized designs. A total of 303 immunocompromised patients were studied. Mean patient age was 57.3 years. Immunosuppressant medication use was the reason for the immunocompromised state in the majority (77.2%), and 19.2% had greater than one immunocompromising condition. Seventy-six percent were given FMT via colonoscopy. Of the 234 patients with reported follow-up outcomes, 207/234 (87%) reported resolution after first treatment, with 93% noting success after multiple treatments. There were 2 reported deaths, 2 colectomies, 5 treatment-related infections, and 10 subsequent hospitalizations. Conclusion: We found evidence that supports the use of FMT for treatment of CD infection in immunocompromised patients, with similar rates of serious adverse events to immunocompetent patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.